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Abstract
Continuous research into the pathophysiology of psychiatric disorders, such as major depressive disorder (MDD), posttraumatic
stress disorder (PTSD), and schizophrenia, suggests an important role for metabolism. This narrative review will provide an up-
to-date summary of how metabolism is thought to be involved in the pathophysiology of these psychiatric disorders. We will
focus on (I) the important role of fatty acids in these metabolic alterations, (II) whether fatty acid alterations represent epiphe-
nomena or risk factors, and (III) similarities and dissociations in fatty acid alterations between different psychiatric disorders.
(Historical) epidemiological evidence links fatty acid intake to psychiatric disorder prevalence, corroborated by altered fatty acid
concentrations measured in psychiatric patients. These fatty acid alterations are connected with other concomitant pathophysi-
ological mechanisms, including biological stress (hypothalamic-pituitary-adrenal (HPA)-axis and oxidative stress), inflamma-
tion, and brain network structure and function.Metabolomics and lipidomics studies are underway tomore deeply investigate this
complex network of associated neurometabolic alterations. Supplementation of fatty acids as disease-modifying nutraceuticals
has clinical potential, particularly add-on eicosapentaenoic acid (EPA) in depressed patients with markers of increased inflam-
mation. However, by interpreting the observed fatty acid alterations as partly (mal)adaptive phenomena, we attempt to nuance
translational expectations and provide new clinical applications for these novel neurometabolic insights, e.g., to predict treatment
response or depression recurrence. In conclusion, placing fatty acids in context can contribute to further understanding and
optimized treatment of psychiatric disorders, in order to diminish their overwhelming burden of disease.
Introduction
Relevance
Psychiatric disorders including major depressive disorder
(MDD), posttraumatic stress disorder (PTSD), and schizo-
phrenia rank as a distant first in the global burden of disease
estimates regarding years lived with disability, and share this
problematic position with cardiovascular diseases for disabil-
ity adjusted life years (Vigo et al. 2016). The main reasons for
tremendous burden of disease for psychiatric disorders in-
clude (I) their early onset and chronic, recurrent nature
(Mocking et al. 2016a), (II) limited available treatment options
lacking an (etiologically driven) personalized approach
(Bockting et al. 2013), and (III) high cardiovascular comor-
bidity (Assies et al. 2014).
In order to overcome this disease burden, there have been
increasing scientific efforts during the past few decades to
better understand these disorders from a (neuro)biological per-
spective. Initial models — based on serendipitous effects on
mood of drugs that modulated neurotransmitters — focused
on disturbances in the synaptic neurotransmission of mono-
amines as serotonin, dopamine, and noradrenaline (Hirschfeld
2000; Ruhe et al. 2007). While these monoamine hypotheses
certainly have advanced the field of biological psychiatry, it is
increasingly being recognized that they only tell a small part
of the complex story of psychiatric disorder pathophysiology
(Su 2008; Gardner and Boles 2011).
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More recent hypotheses suggest broader metabolic alter-
ations that extend beyond monoamine metabolism (Su 2008;
Maes et al. 2009; Assies et al. 2014; Naviaux 2014; Rosenblat
et al. 2014;Muller et al. 2015;Mocking et al. 2016a). Complex
interacting metabolic pathways are being hypothesized to part-
ly underlie — and be connected with — observed coexistent
biological (oxidative) stress, inflammatory, and brain network
alterations. Within these pathways, a metabolic factor that par-
ticularly attracted increasing scientific attention in the past few
decades was fatty acid metabolism (Fig. 1). Several lines of
evidence link fatty acid alterations to psychiatric disorders, and
suggest interesting cross-links between fatty acids and other
pathophysiological mechanisms as outlined below. This pro-
posed role of fatty acids in psychiatric disorder pathophysiol-
ogy could yield important new insights in (I) psychiatric dis-
order incidence and their recurrent, chronic nature, (II)
development of new treatment strategies, and (III) reduction
of cardiovascular comorbidity.
Methods
In this narrative review, we will provide an up-to-date sum-
mary of how fatty acids and their oxygenated products are
thought to be involved in psychiatric disorder pathophysiolo-
gy. We searched for articles on the roles of fatty acids in
psychiatric disorders in PubMed and Google Scholar using
keywords on fatty acids (e.g., unsaturated fatty acids, arachi-
donic acid, eicosapentaenoic acid, essential fatty acids, mono-
unsaturated fatty acids, omega-3 fatty acids, docosahexaenoic
acid, omega-6 fatty acids, lipid peroxidation products, mem-
brane lipids, fish oils, polyunsaturated fatty acids, or saturated
fatty acids). In addition, we searched reference lists and cited
Fig. 1 Simplified scheme depicting the different roles of fatty acids in the
phospholipid cel l membrane and associat ions with other
pathophysiological mechanisms. Not all fatty acids are created equal,
they can be subdivided into three main classes: saturated (no double
bonds), mono-unsaturated (one double bond), and polyunsaturated
(multiple double bonds). Mono- and poly-unsaturated fatty acids are
subdivided based on carbon atom number from which the first double
bond is positioned, counted from the methyl end of the fatty acid chain
(e.g., in omega-3 fatty acids, the first double bond is located between the
third and fourth carbon atom). In addition, fatty acids from all three main
classes can be characterized as Blong-chain^ if they have ≥20 carbon
atoms in their chain. The brain consists of >50% of fat. Zooming in,
synapses are composed of a phopholipid bilayer neuronal membrane.
The more unsaturated fatty acid (more double bonds) it contains, the
more fluid the membrane becomes (left side of the membrane fatty
acids panel). However, double bonds are vulnerable for oxidation.
Oxidation products from omega-3 fatty acids are generally anti-
inflammatory, those of omega-3 fatty acids are pro-inflammatory (lower
side). Omega-3 and omega-6 fatty acids cannot be synthesized, and have
therefore be derived from the diet, they can be metabolized by desaturase
and elongase enzymes (shown right). Activation of the hypothalamic-
pituitary-adrenal (HPA) axis (shown left in purple arrows) results in
production of cortisol, which activates intrinsic feedback loops (in red).
Cortisol has bidirectional relationships with fatty acid metabolism (gray
dotted arrows), e.g., it inhibits desaturases and elongases, influences
mobilization of fatty acids, and increases oxidation; while omega-3
fatty acids reduce cortisol, increase negative feedback, and
inflammation stimulates the hypothalamus
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articles for additional articles. Articles were selected based on
relevance and quality, as determined by critical assessment
and discussion among the review team.
In part 2 we will first describe why fatty acids may be of
interest in psychiatric disorder pathophysiology, in part 3 we
will describe fatty acid studies in psychiatric disorders, follow-
ed by a discussion in part 4. Throughout the manuscript, we
will focus on (I) fatty acids’ role in the metabolic and associ-
ated pathophysiological alterations, (II) whether fatty acid al-
terations represent epiphenomena, adaptive mechanisms, or
risk factors, and (III) similarities and dissociations in fatty acid
alterations between different psychiatric disorders. By
interpreting fatty acid alterations as partly (mal)adaptive phe-
nomena, we aim at nuancing translational expectations and
providing new clinical applications.
Why fatty acids?
Epidemiological evidence
Ecological, cross-sectional, and prospective data
Humans are incapable of de novo omega-3 and -6 polyunsat-
urated fatty acid synthesis, and therefore depend on dietary
intake of these essential nutrients (Assies et al. 2014). This
essential nature could underlie several lines of epidemiologi-
cal evidence suggesting an inverse association between die-
tary omega-3 fatty acid intake and the prevalence of psychiat-
ric disorders. A first hint of this inverse association was pro-
vided in 1998 by ecological evidence showing a lower prev-
alence of psychiatric disorders in countries where more (fatty)
fish is being consumed, the main dietary source of fatty acids
(Hibbeln 1998; Hibbeln 2002; Grosso et al. 2014). Later, more
detailed cross-sectional studies largely supported this ecolog-
ical evidence (Grosso et al. 2016; Li et al. 2016). In addition,
prospective studies generally also corroborated this relation-
ship (Sanhueza et al. 2013; Vermeulen et al. 2016), providing
further support for a possible causal relationship. For example,
we recently showed that a higher baseline dietary pattern
score, also based on omega-3 fatty acid intake, protected
against depression over a 9-year period in the InChianti study
(Vermeulen et al. 2016).
Comorbidity patterns
Additional epidemiological evidence for a role for fatty acid
abnormalities in psychiatric disorders is found in comorbidity
patterns. The high comorbidity rate of psychiatric disorders
with cardiovascular disease may hint at a partly shared under-
lying pathophysiology. Because both are associated with sim-
ilar alterations in fatty acid intake, this may suggest that these
fatty acids are involved in their mutual pathophysiology. In
this regard, psychiatric and cardiovascular disease have been
suggested to represent two sides of the same coin (Assies et al.
2014). Furthermore, diseases caused by genetic disturbances
in fatty acid metabolism such as peroxisomal disorders includ-
ing X-linked adrenoleukodystrophy (McNamara 2013), can
cause psychiatric symptoms including psychosis, anxiety,
and depressive behavior (Kitchin et al. 1987). Of note, one
study reported that 39% of X-linked adrenoleukodystrophy
patients presented with a psychiatric diagnosis, sign or symp-
tom, including mood symptoms, PTSD, and schizophrenia
(Kitchin et al. 1987).
Historical epidemiological perspective
Interestingly, historical epidemiological data also suggest an
association between an increase in psychiatric disorder prev-
alence and a decrease in omega-3 fatty acid intake— together
with a relative increase in omega-6 fatty acid intake (Grosso
et al. 2014). Over the past 100–150 years, the ratio of omega-6
to omega-3 fatty acids in our modernWestern diets has shown
a steep increase from ~1–2:1 to ~20–30:1. Although alterna-
tive explanations have also been suggested (Dehue 2008;
Bracke et al. 2016), this may have contributed to a suggested
parallel rise in burden of disease due to psychiatric disorders
(Simopoulos 1999; Muskiet 2010; Hidaka 2012; Grosso et al.
2014; van Elst et al. 2014). Similar observations in more re-
cently modernizing countries could suggest that history re-
peats itself (Sun and Ryder 2016). We recently aimed at test-
ing the hypothesis of a mismatch between our modern diet and
our evolution-based biological make-up, and showed a posi-
tive association between a dietary mismatch score and depres-
sion in a large interethnic population study, that survived cor-
rection for confounders (Nederhof 2016).
Biological evidence
Lipids constitute more than half of brain dry weight, of which
approximately one third is accounted for by polyunsaturated
fatty acids (Guest et al. 2013), by forming the main building
blocks of (neuronal) cell membranes (Piomelli et al. 2007;
Holthuis and Menon 2014). Through their functional and
structural characteristics, fatty acids influence brain physiolo-
gy in multiple ways, e.g., affecting neuronal membrane struc-
ture, inflammatory regulation, hypothalamic-pituitary-adrenal
(HPA)-axis activity, and oxidative stress vulnerability (Fig. 1),
as described below.
Neuronal membrane structure
Fatty acids form the hydrophobic tails of membrane phospho-
lipids (Piomelli et al. 2007; Assies et al. 2014; Holthuis and
Menon 2014). Double bonds cause curvatures in
(poly)unsaturated fatty acids. If phospholipids contain fatty
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acids with more double bonds, the resulting curvatures de-
crease adhesive van der Waals forces between them, produc-
ing a more fluid membrane. The other way around, the straight
saturated fatty acids can be more tightly packed, resulting in a
more rigid/stiff membrane. The fluidity of the membrane in-
fluences lipid-protein interactions of membrane-bound pro-
teins as neurotransmitter-receptors and –transporters (Fisar
2005; Rituper et al. 2010; Pengcheng Fan 2015). Thereby,
(neuronal) membrane fatty acid composition can influence
synaptic communication, providing an important potential
pathway through which fatty acids may be involved in neuro-
nal connectivity and thereby in psychiatric disorder patho-
physiology (Piomelli et al. 2007; Assies et al. 2014;
Holthuis and Menon 2014). As an example, the geometrical
characteristics of fatty acids in the presynaptic membrane have
been suggested to facilitate exocytosis of neurotransmitter-
containing synaptic vesicles (Piomelli et al. 2007).
Inflammatory regulation
Through (non)enzymatic oxygenation, fatty acids form the
precursors of inflammatory regulating molecules such as ei-
cosanoids, including prostaglandins and leukotrienes (Calder
2006). Importantly, inflammatory mediators derived from
omega-3 and omega-6 fatty acids are thought to have oppos-
ing effects: those from omega-3 fatty acids are considered
anti-inflammatory, while those of omega-6 fatty acids are gen-
erally pro-inflammatory. Of note, omega-3 and omega-6 fatty
acids compete for the same enzymes for metabolization, not
only in fatty acid chain remodeling (e.g., elongation and
desaturation), but also mobilization (e.g., phospholipase A2-
mediated membrane release) as well as inflammatory media-
tor production (e.g., cyclooxygenase-mediated prostaglandin
production) (Calder 2006; Kiecolt-Glaser et al. 2015). So a
greater omega-6 fatty acid supply to these enzymes implies
less metabolization capacity for omega-3 fatty acids. This po-
tentially aggravates their mutually antagonizing effects. Given
that many psychiatric disorders are thought to be characterized
by increased inflammation (Sommer et al. 2012; Kiecolt-
Glaser et al. 2015), the increase in dietary omega-6/omega-
3-ratio described above may have an important underlying
role. This inflammatory modulating effect could also explain
the association of fatty acids with cardiovascular disease.
Bidirectional relation with hypothalamic-pituitary-adrenal
(HPA)-axis
One of the most-studied pathophysiological mechanisms in
biological psychiatry is neuroendocrinological stress, quanti-
fiable in HPA-axis activity leading to production of cortisol
(Stetler and Miller 2011). Interestingly, fatty acids influence
both HPA-axis stimulation and feedback through their effects
on corticotropin-releasing hormone (CRH)-secretion and
glucocorticoid receptor-sensitivity. In brief, lower concentra-
tions of omega-3 fatty acids and relatively higher concentra-
tions of omega-6 fatty acids are thought to lead to HPA-axis
hyperactivation, i.e., cortisol increases (Hibbeln and Salem
1995; Murck et al. 2004; Mocking et al. 2012a, 2013b;
Bazinet and Laye 2014; Mocking et al. 2015). Vice versa,
cortisol influences production, mobilization, and degradation
of fatty acids by modulating key enzymes and increasing ox-
idative stress. In short, the result is that increases in cortisol
lead to lower omega-3 fatty acid concentrations (Hibbeln and
Salem 1995; Macfarlane et al. 2008; Mocking et al. 2013b).
These proposedly bidirectional effects could potentially lead
to a Bvicious^ circle, where a decrease in omega-3 fatty acids
would result in increases in cortisol, which on its turn would
further decrease omega-3 fatty acid concentrations. In addi-
tion, this process could be one of the components of the
allostatic load of chronic stress, also leading to cardiovascular
disease (Juster et al. 2010).
Oxidative stress vulnerability
Fatty acids strongly differ in their susceptibility to free radical
attack, based on the number of double bonds. With every
double bond, a fatty acid becomes exponentially more suscep-
tible (Assies et al. 2014). Of note, many psychiatric disorders
manifest themselves together with an increase in oxidative
stress, defined as an imbalance between increased free radical
formation on the one hand, and decreased anti-oxidant defense
on the other (Maes et al. 2009; Assies et al. 2014; Black et al.
2015). This may lead to interesting interactions with fatty acid
metabolism (Assies et al. 2014) as discussed below.
Other mechanisms
Fascinatingly, fatty acids have also been associated with a
wide variety of other (patho)physiological mechanisms. For
example, they are precursors of endocannabinoids (Meijerink
et al. 2013; Naughton et al. 2013), sphingolipids, and lipid
oxidation products (lipoxins) as resolvins, maresins, and
protectins (Schneider et al. 2016). Endocannabinoids are
neuromodulatory lipids derived from omega-6 arachidonic
acid, and thought to be involved in regulation of mood and
psychosis vulnerability. (Neuro)protectin D1 is an oxidative
derivative from the omega-3 fatty acid docosahexaenoic acid
(DHA), and has anti-apoptotic and thereby neuroprotective
properties.
In addition, fatty acids have nutrigenomic effects, i.e., they
can regulate gene-expression. As an example, several fatty
acids and their oxidative derivatives are endogenous ligands
to peroxisome proliferator-activated receptors (PPARs), im-
portant transcription factors for regulation of metabolism and
cellular development (Mutch et al. 2005). In addition, bymod-
ulating cyclic AMP-dependent response element binding
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protein (CREB) through a p38 mitogen-activated protein ki-
nase (MAPK)-dependent mechanism, omega-3 fatty acids
have also been shown to influence brain derived neurotrophic
factor (BDNF), an important regula tor of brain
cytoarchitecture (Rao et al. 2007).
Finally, fatty acids have been reported to influence the gas-
trointestinal microbiome (Pusceddu et al. 2015); and are asso-
ciated with one-carbon metabolism and thereby epigenetics
(through methyl-group donation for DNA methylation)
(Muskiet and Kemperman 2006; Assies et al. 2015).
Regarding this latter association, we previously described sev-
eral ways through which fatty acids can influence one-carbon
metabolism, including regulation of oxidative stress, methyl-
group donation for fatty acid chain elongation, and epigenetic
regulation (Assies et al. 2014).
Fatty acid studies in psychiatric disorders
In this third part we will first describe studies that investigated
the association between fatty acid alterations and psychiatric
disorder. We will start with cross-sectional studies, and then
describe longitudinal studies. Subsequently we will review
studies on the association between fatty acid alterations and
other pathophysiological mechanisms in psychiatric disorders.
Finally, wewill provide an overview of clinical applications of
fatty acids in psychiatry, including intervention studies.
Associations between fatty acid alterations
and psychiatric disorders
Cross-sectional observational studies
The above epidemiological and biological data on fatty acid
metabolism in psychiatric disorders increasingly stimulated
research in fatty acid alterations in patients. Cross-sectional
studies in several psychiatric disorders generally show associ-
ations with a pattern of decreased concentrations of omega-3
fatty acids, and an increased omega-6/omega-3-ratio
(Freeman 2000; Haag 2003). Evidence seems to be strongest
for major depressive disorder (Lin et al. 2010), but a similar
pattern seems to exist for schizophrenia (Hoen et al. 2013).
Anxiety disorders are less extensively studied (Ross 2009; de
Vries et al. 2016); we previously found lower DHA in PTSD
patients compared to controls, but only after correction for diet
(de Vries et al. 2016).
Importantly, several negative findings have been published
as well (Lin et al. 2010; Hoen et al. 2013; Mocking et al. 2015;
Medema et al. 2016). A wide range of methodological issues
could explain these inconsistencies. First, statistical methodo-
logical issues regarding fatty acid expression and testing may
influence reported fatty acid alterations, including correct han-
dling of non-detects, expression of fatty acids in relative
percentages or absolute concentrations, and multiple testing
problems (Mocking et al. 2012c). For example, using zero-
substitution for non-detectable values may artificially lower
statistical estimates of mean concentrations. In addition, some
studies express fatty acids as relative percentages of the total
fatty acid pool, while other studies use absolute concentra-
tions, which may influence the extent of the differences.
Finally, given the large number of different fatty acids, multi-
ple testing issues may induce type I errors, for which many
studies do not systematically correct (Mocking et al. 2012c).
Second, results may be influenced by the focus on omega-3
and omega-6 PUFAs instead of the overall fatty acid alteration
pattern (Assies et al. 2010). Given the unique properties of the
essential fatty acids of the omega-3 and -6 subclasses, most
studies focused on these fatty acids. Nevertheless, increasing
data suggest that fatty acid alterations in psychiatric disorders
extend beyond the omega-3 and -6 subtypes, and can also be
observed in saturated and monounsaturated fatty acids (Assies
et al. 2010; Assies et al. 2014). This suggests patterns of al-
terations in fatty acids and their oxygenated products that can
be better studied using lipidomic or metabolomic approaches
as are currently increasingly being applied.
In addition, evidence is available suggesting bimodal dis-
tributions of fatty acid concentrations, which may influence
statistical interpretations. For example, following observa-
tions of bimodal distributions of polyunsaturated fatty acids
in schizophrenia (Bentsen et al. 2011), we showed that overall
fatty acid unsaturation and chain length were also bimodally
distributed in recurrent depression (Mocking et al. 2012b).
This bimodal distribution has been suggested to represent
two endophenotypes (Bentsen et al. 2011).
Alternatively, the inconsistencies in cross-sectional find-
ings could be explained by confounding, e.g., due to lifestyle
or medication use (Assies et al. 2014). This may suggest that
the observed association between psychiatric disorders and
fatty acid alterations merely reflect epiphenomena of the dis-
ease, instead of risk factors. One important lifestyle factor is
diet. Not all studies apply standard corrections for dietary
intake (Lin et al. 2010). In addition, diet is difficult to measure
and residual confounding after correction could still influence
results. Nevertheless, it could be questioned whether diet
should be seen as a confounder. If differences in dietary intake
lead to altered fatty acid concentrations that increase disease
risk, fatty acids could instead be seen as mediators of the effect
of differences in dietary intake (Assies et al. 2014). A more
definitive answer on whether fatty acids should be seen as
epiphenomena or risk factors can be found by prospective
cohort and intervention studies as described below.
Regarding medication use, several (psychotropic) medica-
tions may theoretically affect fatty acid concentrations and
intake. Some studies investigated fatty acids exclusively in
medication free subjects (Lin et al. 2010; Mocking et al.
2015, 2017a), but in general the precise effects of the different
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medications on fatty acid concentrations have not been sys-
tematically studied in psychiatric patients. Nevertheless, the
relation between metabolic alterations and psychiatric dis-
eases was already observed well before the development of
psychotropic medication (Assies et al. 2014). Larger samples
and individual patient data meta-analyses, providing the op-
portunity to study the association between medication use and
fatty acids in more detail, may yield more insight on the po-
tential confounding effects of medication use.
Furthermore, fatty acid alterations have been mostly stud-
ied in peripheral samples, e.g., erythrocyte membranes, given
the impossibility of in vivo brain tissue sampling.
Nevertheless, (I) blood concentrations generally shown ade-
quate correlations with central measures, as shown in vivo in
cerebrospinal fluid, as well as in postmortem and animal stud-
ies (Carlson et al. 1986; Connor et al. 1990; Babin et al. 1993;
Makrides et al. 1994; Carver et al. 2001; Yao et al. 2002;
Cunnane et al. 2012; Jumpertz et al. 2012; Guest et al.
2013), (II) fatty acids both passively and actively cross the
blood-brain-barrier (Chen et al. 2008; Mitchell et al. 2011),
and (III) findings in post-mortem brains generally corroborate
findings from peripheral samples for psychiatric disorders
(McNamara and Carlson 2006; Hamazaki et al. 2012;
McNamara et al. 2014).
Overall, these cross-sectional findings show a general pic-
ture of reduced concentrations of omega-3 fatty acids and an
increase in omega-6/omega-3 ratio in at least depression and
schizophrenia. Some transdiagnostic studies have aimed to
compare fatty acid pattern alterations between psychiatric dis-
orders (Hamazaki et al. 2012; Hamazaki et al. 2015), but ev-
idence is still limited in that regard (Ross et al. 2007).
Longitudinal observational studies
Similar to the above cross-sectional data, prospective studies
on the relationship between fatty acids and depression show
substantial heterogeneity (Lucas et al. 2011; Grosso et al. 2014;
Matsuoka et al. 2017). Although other fatty acid classes have
also been prospectively studied, most studies again focused on
omega-3 fatty acid concentrations or intake. A meta-analysis
of prospective studies showed a protective effect for both fish
and EPA +DHA intake on the development of depression over
a follow-up of up to 30 years (Grosso et al. 2016). Associations
remained after controlling for dietary and socio-economic var-
iables. For omega-3 fatty acid concentrations as biomarkers as
opposed to intake, results seem somewhat more inconsistent,
with some studies showing a protective association (Beydoun
et al. 2015; Berger et al. 2017), and others no relationship
(Astorg et al. 2009; Persons et al. 2014). Additional supportive
evidence for a prospective relationship comes from studies
showing fatty acid alterations that remain during remission
(Assies et al. 2010).
Longitudinal data for psychotic disorders show a similar
prospective association for both fatty acid intake and concen-
trations during different stages of the disease (McGorry et al.
2014). Next to protective associations for omega-3 fatty acid
intake and concentrations, evidence also exists for a protective
effect of omega-9 fatty acid nervonic acid concentrations, a
major constituent of myelin membrane sphingolipids
(Amminger et al. 2012).
Associations with other pathophysiological mechanisms
As described above in Biological evidence, through their pro-
posed central role in (patho)physiology, fatty acids may have
multiple relationships with other pathophysiological mecha-
nisms relevant in psychiatric disorders and cardiovascular dis-
ease (Hibbeln and Salem 1995). Here, we describe clinical
studies that addressed the relationship between fatty acid me-
tabolism and (I) brain networks, (II) inflammation, (III) the
HPA-axis, and (IV) other mechanisms.
Brain networks A vast body of evidence shows alterations in
brain networks in patients with psychiatric disorders (Broyd
et al. 2009; Rive et al. 2013; Kaiser et al. 2015). The relations
of fatty acid metabolism with brain structure and BDNF de-
scribed above in Neuronal membrane structure and Other
mechanisms are reflected in emerging evidence associating
fatty acids with brain network structure and function
(McNamara 2013; Bos et al. 2016). For example, omega-3
fatty acids were found to be positively associated with (I)
white matter integrity (Peters et al. 2013; Peters et al. 2014)
and brain glutathione (a major antioxidant) in schizophrenia
(Berger et al. 2008); (II) limbic area volumes in healthy con-
trols (Conklin et al. 2010; McNamara 2013;Witte et al. 2014);
and (III) activity in depression relevant areas like the prefron-
tal and anterior cingulate cortex (McNamara 2013). Our own
research showed an association between arachidonic acid and
amygdala reactivity that differed between unmedicated pa-
tients with depression and healthy matched controls
(Mocking et al. 2017a). However, most studies have modest
sample sizes, and in the absence of prepublished analysis pro-
tocols multiple testing problems may exist, given the multi-
tude of possible operationalizations of both fatty acid and
imaging parameters (Mocking et al. 2012c).
InflammationMany psychiatric disorders have been associat-
ed with increased inflammation, including depression, schizo-
phrenia, and PTSD (Raison and Miller 2011; Sommer et al.
2014). The relation between fatty acid metabolism and inflam-
mation described above in Inflammatory regulation is
reflected in corresponding associations with inflammatory
biomarkers as C-reactive protein (CRP) and cytokines
(Calder 2006; Mazza et al. 2015). In unmedicated depressed
patients, we observed a positive association between
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arachidonic acid and CRP, that both were present in higher
concentrations than in matched controls (Mocking et al.
2017a). Another interesting clinical example illustrating the
inflammatory modulating effects of fatty acids, is that a higher
— i.e., more pro-inflammatory — omega-6/omega-3-ratio
seems to predict depression onset during treatment with the
inflammatory cytokine interferon-alpha in hepatitis C-patients
(Lotrich et al. 2013; Su 2015).
HPA-axis Particularly, stress related disorders, such as depres-
sion and PTSD, have been shown to be associated with HPA-
axis alterations. While PTSD is mainly characterized by
blunted cortisol responses (Meewisse et al. 2007; Bicanic
et al. 2013); depressed patients (particularly those with severe
and/or melancholic depression) show HPA-axis hyperactivity
thought to result from impaired HPA-axis feedback through
the glucocorticoid receptor (Pariante et al. 2004; Stetler and
Miller 2011; Lok et al. 2012). The Bvicious^ circle, potentially
resulting from the bidirectional relationship between fatty acid
metabolism and the HPA-axis (described in Bidirectional re-
lation with hypothalamic-pituitary-adrenal (HPA)-axis) fits
with our observations of associations between fatty acid me-
tabolism and cortisol in depression. In detail, in two indepen-
dent cohorts of depressed patients, we observed a similar neg-
ative association between fatty acid unsaturation and salivary
cortisol. Given that one of these cohorts showed
hypercortisolism and the other did not, the relation between
fatty acid metabolism and the HPA-axis may be more consis-
tently altered than each system separately (Mocking et al.
2013b, 2015).
Clinical applications
Correcting fatty acid alterations: intervention studies
Lifestyle The above data on a role of fatty acid alterations in
psychiatric disorder pathophysiology resulted in several trials
aiming at correcting these alterations. Instead of
supplementing omega-3 fatty acids as discussed in the next
paragraph, the most (physio)logical way to increase omega-3
fatty acid concentrations would be to eat more omega-3 fatty
acids (e.g., fatty fish) and less omega-6 fatty acids. Several
dietary trials are underway in psychiatric disorders, some al-
ready show potential of dietary modification, including in-
creasing omega-3 fatty acid intake, e.g., from nuts and fish
(Berk et al. 2013; Sarris et al. 2015; Opie et al. 2016). For
example, in depression, a relatively well-conducted 12-week
single blind randomized controlled trial of an adjunctive die-
tary intervention vs. a social support protocol showed a num-
ber needed to treat of 4.1 for remission (Jacka et al. 2017).
Moreover, combining increased dietary omega-3 fatty acid
intake with other dietary and lifestyle factors decreasing oxi-
dative stress, e.g., physical exercise, seems particularly
promising (Gomez-Pinilla 2011; Berk et al. 2013; Daumit
et al. 2013; Roca et al. 2016; Naslund et al. 2017). For exam-
ple, an intervention composed of exercise and dietary man-
agement (vs. standard health classes) in obese persons with
serious mental illnesses, such as schizophrenia, bipolar disor-
der or major depression, led to more weight loss than compa-
rable lifestyle-intervention trials in the general population
(Daumit et al. 2013).
Fatty acid supplementationDespite the above promising find-
ings for lifestyle modification, it generally seems hard to fol-
low and maintain dietary guidelines. Many people do not yet
manage to increase their dietary omega-3 fatty acid intake
(Sarris et al. 2015). Therefore, several trials attempted to cor-
rect fatty acid alterations using supplements. Most trials sup-
plemented omega-3 fatty acids, mainly in the form of
eicosapentaenoic acid (EPA) and/or docosahexaenoic acid
(DHA). Some studies also supplemented arachidonic acid or
other fatty acids. Most trials have been performed for mood
disorders, some studies included patients with psychotic, anx-
iety or other disorders, including attention deficit hyperactiv-
ity disorder, autism, or aggression (Gesch et al. 2002;
Zaalberg et al. 2010; Berger 2016; Bozzatello et al. 2016).
Below we will briefly discuss recent findings in psychosis
prevention, and elaborate on the interesting debate on
omega-3 fatty acid supplementation in depression.
In schizophrenia, there has been recent attention for
omega-3 fatty acids to prevent psychosis in ultra-high risk
individuals. A promising study in young adults aged 13 to
25 years with subthreshold psychosis showed that 12-weeks
omega-3 fatty acid supplementation reduced progression to
psychotic disorder and general psychiatric morbidity over
multiple years (Amminger et al. 2010; Amminger et al.
2015). However, the multicenter NEURAPRO study failed
to replicate these initial hopeful findings (McGorry et al.
2017). Besides actual lack of a true effect, some other reasons
can be thought of for this non-replication, including a ceiling
effect caused by a low transition rate due to concurrent psy-
chosocial and antidepressant treatment (62% vs. 10% in the
original study); nonstudy omega-3 fatty acid intake;
nonadherence (>50%); or subgroup effects.
For depression, in general, both study quality and effect
sizes of omega-3 supplementation studies are modest (Bloch
and Hannestad 2012). However, compared to studies of other
available treatment options including antidepressants, the ef-
fects of omega-3 fatty acid supplementation seem to hold up.
Because of the ongoing debate on omega-3 fatty acid supple-
mentation for depression, we will describe the results in more
detail in order to nuance findings.
Overall, meta-analytic standardized mean differences for
omega-3 fatty acids compared to placebo for depression gen-
erally range from 0.11 to 0.56 (Appleton et al. 2015). However,
interestingly, meta-analysis outcomes seem to depend on
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individual study characteristics: larger effects are seen for stud-
ies that supplement EPA to patients with major depressive
disorder, as opposed to negligible or absent effect in studies
that supplement DHA to subjects with only depressive symp-
toms or as preventive intervention (Martins 2009; Lin et al.
2012; Martins et al. 2012).
A recent Cochranemeta-analysis of omega-3 fatty acid sup-
plementation for depression observed an overall effect size of
0.30 (95%CI = 0.10–0.50) (Appleton et al. 2015). However,
the authors conclude that this significant small-to-modest ef-
fect size has small clinical significance because the approxi-
mate reduction in Hamilton depression rating scale (HDRS)-
score of 2.1 points remains under the National Institute for
Health and Care Excellence (NICE)-limit of 3 points for clin-
ically meaningful effects. In addition, the authors are critical in
their qualification of study quality. For example, studies that
did not add a small amount of fish oil to the placebo to mask a
possible fishy aftertaste were judged to be at high risk of bias.
Nevertheless, the Cochrane meta-analysis acknowledges
that the overall effect size for omega-3 fatty acids is compara-
ble to that of antidepressants (Appleton et al. 2015). The au-
thors described that the only available study that directly com-
pared omega-3 fatty acids and antidepressant showed compa-
rable benefit, but that the quality of the evidence is low.
Nevertheless, they also describe that the reported combined
meta-analytic effect size of omega-3 fatty acids of 0.30
(95%CI = 0.10–0.50) is comparable to that of antidepressants:
0.32 (95%CI = 0.25–0.40). The CI is more narrow for antide-
pressants, suggesting that for omega-3 fatty acid the effect size
may be either more clinically important or possibly negligible.
Based on this data, the authors suggest that the comparable
small-to-modest overall effect for both omega-3 fatty acids
and antidepressants merely shows the need for other effective
treatments. While there obviously is a need for other more
effective treatments, given that omega-3 fatty acids are gener-
ally thought to have a more beneficial side effect and tolera-
bility profile than antidepressants, these outcomes could also
be interpreted in a way suggesting that omega-3 fatty acids
may have a role as (add-on) treatment for depression.
Moreover, the Cochranemeta-analysis shows stronger ben-
eficial effects in the subgroup of studies supplementing solely
or predominantly EPA, and in studies that did not use the
omega-3 fatty acid alpha-linolenic acid (the precursor of
EPA and DHA) as placebo (Appleton et al. 2015).We recently
corroborated this finding in an a priori specified meta-
regression analysis showing a linear dose-response relation-
ship for EPA (Mocking et al. 2016b). In addition, our meta-
regression analysis suggests that omega-3 fatty acids are more
effective when given in addition to antidepressants, i.e.,
augmentation/add-on studies (Mocking et al. 2016b).
Furthermore, we recently showed a large meta-analytic effect
size for omega-3 fatty acid supplementation specifically for
women with post-partum depression (Mocking et al. 2017b).
In conclusion, with (I) an overall effect size comparable to
that of antidepressants, (II) a side effect profile that is consid-
ered to be relatively safe and tolerable, (III) relative low-costs,
and (IV) a larger effect size in studies supplementing EPA next
to antidepressants, omega-3 fatty acids may hold clinically
meaningful potential, especially when prescribing EPA as an
augmentation strategy in major depressive disorder. An extra
potential advantage is that omega-3 fatty acid supplementa-
tion might have a parallel beneficial effect on comorbid
(cardiovascular) conditions as well (Mozaffarian and Wu
2011).
This line of thought has not yet been implemented in clin-
ical practice. Guidelines and handbooks on depression often
do not even mention omega-3 fatty acids (Sarris et al. 2015).
This may have to do with the relatively small sample sizes of
the performed studies (total N of the Cochrane meta-analy-
sis = 1438), resulting in relatively wide confidence intervals
(Appleton et al. 2015). However, pooled confidence intervals
for most meta-analytic outcomes of omega-3 fatty acids for
depression (including the Cochrane’s) do not cross zero, and
while these pooled meta-analytic confidence intervals include
negligible effects, they also include relatively large effects
(Appleton et al. 2015). Concerns that have been raised of
publication bias and distortion due to sponsoring seem at most
comparable to that for antidepressants. Nevertheless, the ad-
age primum non noceremay withhold clinicians from clinical
implementation. Additional evidence could come from larger
but well-executed, long-term, clinical trials that (I) supplement
EPA in an add-on design and (II) have attention for biochem-
ical and clinical potential side effects, as discussed below and
elsewhere (Assies et al. 2011; Assies et al. 2014). These trials
may convince clinicians and guideline-makers to implement
omega-3 fatty acid supplementation for depression in clinical
practice.
Other clinical applications
Next to supplementation to correct alterations, fatty acids
could also be used in other ways to help psychiatric patients.
A promising alley could be to determine (the pattern of) fatty
acid alterations as part of biomarker panels to personalize
medicine, e.g., to improve prediction of prognosis or treatment
response.
Although most studies focused on finding fatty acid dif-
ferences between patients and controls and/or how to cor-
rect these differences, some studies aimed at using fatty
acids as biomarkers to predict clinical outcome. As an ex-
ample, in the study mentioned earlier in subjects with ultra-
high risk to first-episode psychosis, omega-3 fatty acids
and nervonic acid concentrations aided in predicting tran-
sition into psychosis within 1 year (Clark et al. 2016). In
another study, DHA signaling was one of the top biological
pathways overrepresented in validated biomarkers
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predicting suicidality in samples of women with bipolar
disorder, depression, schizoaffective disorder or schizo-
phrenia and men with bipolar disorder (Le-Niculescu
et al. 2013; Levey et al. 2016). Furthermore, as described
earlier, omega-3 fatty acids and their omega-6 ratio could
predict depression onset during interferon-alpha treatment
(Lotrich et al. 2013). Moreover, fatty acids have been as-
sociated with antidepressant response (Dinan et al. 2009).
In our own study (Mocking et al. 2015, 2017a), we recent-
ly showed that low DHA and high AA were prospectively
associated with non-response of MDD-patients treated
with paroxetine for 12 weeks. Finally, we are currently
examining to what extent fatty acid patterns can predict
recurrence in remitted recurrent depression (Mocking
et al. 2016a).
Fatty acids in inborn errors of metabolism
Fatty acids may play an important role in several inborn
errors of metabolism. A full review of the different potential
roles of fatty acids in these diseases exceeds the scope of this
review, while earlier reviews are available (Fekete and
Decsi 2010; Gil-Campos and Sanjurjo Crespo 2012;
Lohner et al. 2013). In brief, first, several inborn errors of
metabolism require a restricted diet (e.g., phenolketonuria
and organic acidaemias), potentially leading to fatty acid
deficiencies. Indeed, evidence shows reduced omega-3 fat-
ty acid concentrations in these diseases, and suggests bene-
ficial effects of supplementation (Gil-Campos and Sanjurjo
Crespo 2012; Lohner et al. 2013). Second, several inborn
errors of metabolism distort fatty acid metabolism. For ex-
ample, peroxisomal disorders such as X-linked adrenoleu-
kodystrophy distort peroxisomal beta-oxidation of long
chain fatty acids. This results in accumulation of saturated
very-long-chain fatty acids and DHA deficiency (Gil-
Campos and Sanjurjo Crespo 2012). Supplementation of a
mixture of oleic and erucic acid (Lorenzo’s oil) reduces
saturated very-long-chain fatty acid concentrations, but
clinical effects remain under investigation (Ahmed et al.
2016), as well as the effects of omega-3 fatty acid supple-
mentation. Mitochondrial fatty acid oxidation deficiencies
seem to have less influence on omega-3 fatty acid concen-
trations (Gil-Campos and Sanjurjo Crespo 2012). A third
way in which inborn errors of metabolism affect fatty acid
concentrations is through increasing oxidative stress
(Assies et al. 2014). For example, several mitochondrial
disorders may result in increased oxidative stress and there-
by increased peroxidation of omega-3 fatty acids (Gardner
and Boles 2011). The precise (long-term) clinical conse-
quences of these findings have yet to be further elucidated
(Fekete and Decsi 2010; Gil-Campos and Sanjurjo Crespo
2012; Lohner et al. 2013).
Discussion
Integration of findings
Central role of fatty acids
Taken together, evidence for an important role of fatty acid
metabolism in the pathogenesis of psychiatric disorders is in-
creasing. Alterations in fatty acids are of etiological interest,
because they are essential components of all outer and subcel-
lular cell membranes (Crawford et al. 2013; Assies et al.
2014). This is represented by their widespread associations
with other pathophysiological systems including biological
stress (HPA-axis and oxidative stress), inflammation, and
brain network structure and function.
Epiphenomena, adaptive roles or risk factors
Whether fatty acid alterations represent epiphenomena, adap-
tive mechanisms or risk factors is certainly more difficult to
disentangle. Based on the data presented in this review, sev-
eral arguments can be made for a causal role. First, diseases
with genetic defects in fatty acid metabolism (e.g., X-ALD)
have been associated with psychiatric symptoms. Second,
correcting fatty acid alterations seems to improve psychiatric
symptoms. Third, associations are not only cross-sectional,
but also prospective, and have a historical epidemiological
and biological rationale. Nevertheless, given the complexity
and multitude of factors influencing fatty acid metabolism,
epiphenomenal effects cannot be ruled out yet. Psychiatric
disorders are often characterized by suboptimal lifestyles,
which may have profound impact on fatty acid metabolism.
For example, both diet, smoking, and physical inactivity, but
also medication may influence fatty acid concentrations and
cause the observed alterations, e.g., by increasing oxidative
stress (Assies et al. 2014). Nevertheless, these resulting fatty
acid alterations may partially mediate detrimental effects of a
suboptimal lifestyle on mental health. In Future research we
propose studies that could potentially further tease out these
intertwined effects.
Weighing the evidence
Which fatty acid and why?
An interesting observation is that while DHA is the fatty acid
that is most consistently found in lower concentrations in pa-
tients with psychiatric disorders, it is EPA that seems to have
more clinical efficacy, particularly in depression. This ques-
tions the rationale that low DHA resembles a shortage/deficit
that should be corrected by supplementation (Assies et al.
2014). In addition, while DHA is the most abundant fatty acid
in the brain, EPA only represents ≤1% of total brain fatty acids
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(Bos et al. 2016). In addition, although EPA can be trans-
formed into DHA, evidence suggests EPA is rapidly and ex-
tensively ß-oxidized (generating acetyl-CoA) upon entry into
the brain (Bazinet and Laye 2014; Chen and Bazinet 2015).
Because this process results in little to no extra EPA available
in the brain, and the ß-oxidized products are not specific for
EPA, this suggests that EPA’s efficacy cannot be explained by
an effect in the brain, and that EPA is not only a precursor of
DHA but that DHA and EPA have distinct roles.
An explanation could be that the effects of supplemented
EPA are mainly mediated by peripheral anti-inflammatory ac-
tions. EPA, given its multiple double bonds, is prone for en-
zymatic and non-enzymatic oxidation (Assies et al. 2014).
This may be aggravated by the pro-oxidative environment
found in psychiatric disorders (Black et al. 2015).
Particularly, EPA’s eicosanoid oxidation products generally
have anti-inflammatory properties (Calder 2006). Given that
inflammation is thought to underlie many psychiatric disor-
ders including depression (Kiecolt-Glaser et al. 2015), this
could explain why supplemented EPA is more efficacious
than DHA. Interestingly, a recent study corroborated this
view, by showing that inflammation serves as a positive pre-
dictive biomarker for response to omega-3 fatty acid supple-
mentation in depression (Rapaport et al. 2016). In detail, this
proof-of-concept study in 155 depressed patients showed that
combined inflammation biomarkers (IL-1ra, IL-6, hs-CRP,
leptin, adiponectin) could predict response to EPA vs. DHA
or placebo. In detail, only patients with high pre-treatment
inflammation biomarker concentrations benefited significant-
ly more from EPA supplementation (40% remission) com-
pared to DHA (14% remission) or placebo (25% remission).
This suggests that EPA is a promising candidate to reduce the
increased inflammation seen in psychiatric disorders.
Role of oxidative stress
The observation that restoring the low DHA concentrations
seems to have less therapeutic effect, requires an alternative
interpretation of low DHA as a deficit. Although it seems
plausible given the historically epidemiological and biological
evidence presented in this review, a causal deficiency should
result in (clear) improvement after DHA supplementation.
Several explanations might clarify this apparent contradiction.
First, due to its six double bonds, DHA is even more suscep-
tible to oxidation than EPA. If not already oxidized ex vivo in
the supplementation capsules (i.e., becoming rancid), DHA
could easily become oxidized after ingestion in vivo, especial-
ly given the pro-oxidant state observed in psychiatric disor-
ders (Assies et al. 2014). Although supplementation capsules
most often contain tocopherols as antioxidants, these probably
do not provide full protection against oxidation (Halliwell
2000; Naviaux 2012; Assies et al. 2014). Resulting oxidative
metabolites of DHA are not yet routinely measured and
therefore not completely understood, but may induce negative
effects as well (Higdon et al. 2012). This in and ex vivo oxi-
dation of supplemented DHAwould hamper effective restora-
tion of central nervous system DHA concentrations (Assies
et al. 2014).
As an alternative interpretation, low DHA and DHA-
derived lipoxins together with inflammation could be ex-
plained as adaptive processes in reaction to increased oxida-
tive stress. Following this interpretation, cells sense increased
oxidative stress, and in response lower the DHA content of
their membranes, in order to reduce their oxidative stress vul-
nerability. This way, low membrane DHA content and its neu-
ropsychiatric consequences, can be interpreted as a logical by-
product of underlying increases in oxidative stress (Assies
et al. 2014), e.g., from mitochondrial dysfunction (Gardner
and Boles 2011; Morava and Kozicz 2013). Following this
line of thought, it can be expected that Bcorrecting^ this adap-
tive response has no, or even deleterious effects, since addi-
tional DHAwill be oxidized and not incorporated in the mem-
branes. If this hypothesis is correct, instead, it should be tried
to correct the underlying oxidative stress. Although difficult to
implement, oxidative stress could be lowered by, e.g., lifestyle
improvement including stopping smoking, increasing physi-
cal exercise, and limiting excess caloric intake. Indeed, re-
search shows that if oxidative stress can be diminished, fatty
acid alterations seem to (partially) recover (Assies et al. 2014).
For example, bariatric surgery-induced weight loss reduced
lipid peroxidation (Bell et al. 2010).
Nevertheless, to complicate things, reducing inflammation
by EPA supplementation could also reduce oxidative stress,
thereby allowing for reactive DHA increases that may hypo-
thetically partly explain observed therapeutic effects. In addi-
tion, omega-3 fatty acids may have some anti-oxidant effects
on their own and so may directly interfere with increased
oxidative stress (Giordano and Visioli 2014). The net effect
of omega-3 fatty acid supplementation on oxidative stress in
different circumstances has therefore yet to be investigated.
Future research
In order to further disentangle the role of fatty acids and their
oxygenated derivatives in psychiatric disorder pathophysiolo-
gy and to optimally exploit their promise for clinical applica-
tion, several research areas can be further explored. Studies
would benefit from a combined pathophysiological and clin-
ical design, in order to make causal inferences on a biological
level from randomized controlled trials. A potential focus
would be the interplay between oxidative stress and EPA-
supplementation in augmentation studies in depression aiming
at inflammatory modulation. Detailed measurement of oxida-
tion products using lipidomics in a network systems biology
approach, preferably repeatedly during a well-controlled inter-
vention (e.g., lifestyle and/or supplementation), will hopefully
606 J Inherit Metab Dis (2018) 41:597–611
yield meaningful alterations in metabolic patterns. Studying
the dynamics of these network patterns could give insight in
the underlying mutual connections (Naviaux et al. 2016).
Furthermore, personalizing interventions should receive spe-
cial attention. It would be very worthwhile to be able to identify
subgroups of patients [e.g., based on (patterns of) inflammatory
parameters or nutrigenetics (Mutch et al. 2005; Mocking et al.
2013a)] that will benefit from fatty acid supplementation, or to
use fatty acids as markers to identify subgroups of patients that
will benefit from other interventions, e.g., antidepressants or
neurostimulation (given associations of fatty acids with brain
network structure and function). We expect that
pathophysiologically tailored treatment strategies will increase
effect sizes in individual studies and later meta-analyses.
In addition, although possibly less commercially exploit-
able due to the difficulty of producing a marketable product,
interventions aimed at lowering oxidative stress should be
studied. For example, a broad lifestyle intervention focusing
on diet (among others less omega-6), physical activity, and
smoking, with attention for biological and clinical outcomes
may hold great promise to benefit a broad range of disease
outcomes, including cardiovascular and mental health. This
lifestyle intervention would potentially result in a decrease in
oxidative stress and increased co-intake of other essential nu-
trients as Zn, Cu, I, Se, and amino acids. This may have the
additional advantage that increased dietary intake of omega-3
fatty acids can likely be incorporated better (Sarris et al. 2015).
In these studies, it would be commendable to pay attention
to differences in results according to sex, ethnic group where
relevant, and specific ages. For example, although several
studies show gender specific alterations in fatty acids and their
oxidation products in psychiatric disorders (McNamara et al.
2007; Ramos-Loyo et al. 2013; Colangelo et al. 2017), this
factor is not often systematically studied. In addition, more
specific results could be seen if fatty acids would be linked
to pathophysiological dimensions instead of only disorders,
e.g., using the Research Domain Criteria (RDoC) (Insel
2014). In future research, it could also be determined whether
fatty acid alterations and their associated biological processes
(e.g., HPA-axis, inflammation) (I) are factors that alone can
explain psychopathology, (II) should be seen as additive ef-
fects that together cause psychopathology, or (III) instead rep-
resent various (biological) domains of psychopathology.
A more experimental line of research concerns the
quantum-characteristics of fatty acids, particularly DHA.
DHA has been proposed to possess unique properties on a
quantum level. In detail, the molecular structure of DHAwith
its unique six double bonds is thought to facilitate quantum
tunneling of electrons across the membrane (Crawford et al.
2013), allowing for precise depolarization of membranes with
a high DHA content. This may be essential for cells where
rapid and precise depolarization of the membrane is crucial for
adequate cell functioning, such as neurons and retinal cells.
Thereby, DHA’s properties may explain its extreme conserva-
tion— i.e., very high concentrations relative to the rest of the
body — in the synapse and retina. Moreover, consequently,
the development of oxidative metabolism allowing for synthe-
sis of highly unsaturated fatty acid as DHA, has been hypoth-
esized to be a driving facilitator of brain development through
evolution (Crawford et al. 2013). The precise neuroscientific
and clinical consequences of these exciting ideas have yet to
be investigated further.
Conclusion
Although — contrary to some popular belief — omega-3
polyunsaturated fatty acids are certainly nomiracle molecules;
increasing data indicate a role for fatty acid alterations in the
pathophysiology of psychiatric disorders. Together with asso-
ciated pathophysiological systems — including biological
stress (HPA-axis and oxidative stress), inflammation, and
brain network structure and function — fatty acid alterations
form a complex neurometabolic network that seems to alter
the vulnerability for psychiatric disease. Clinically, this
neurometabolic network can be positively influenced by life-
style modification. If this proves to be unfeasible, EPA sup-
plementation may be an effective surrogate in the form of add-
on treatment, particularly in depression, possibly due to its
anti-inflammatory effects. Several lines of research are cur-
rently being explored further, including the use of fatty acids
as biomarkers to predict antidepressant efficacy using
lipidomics. Ultimately, improved neurometabolic insights
could hopefully contribute to a reduction of the large and still
growing burden of disease from psychiatric disorders.
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